Results 231 to 240 of about 573,785 (398)

Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats [PDF]

open access: green, 1992
Wolfgang Linz   +4 more
openalex   +1 more source

Bioactive Compounds Derived From Natural Foods Against Metabolic Syndrome and the Advances of Resveratrol and Caffeic Acid in Microbial Cell Factory Production: A Review

open access: yesFood Frontiers, EarlyView.
Metabolic syndrome is characterized by abdominal obesity, hyperglycemia, dyslipidemia, and hypertension. Bioactive compounds extracted from herbs, tea, and coffee using microbial cell factories, particularly resveratrol and caffeic acid, have demonstrated remarkable potential in the management of metabolic syndrome, offering innovative solutions for ...
Tao Li   +7 more
wiley   +1 more source

Monocyte-to-Neutrophil Ratio as an Immunological Marker of Left Ventricular Hypertrophy in Children with Primary Hypertension. [PDF]

open access: yesJ Clin Med
Dziedzic-Jankowska K   +6 more
europepmc   +1 more source

Left Ventricular Hypertrophy With Strain and Aortic Stenosis

open access: yesCirculation, 2014
Anoop S. V. Shah   +14 more
semanticscholar   +1 more source

Integrative Evidence From Metabolome‐Wide Mendelian Randomization and Animal Models Implicates Tyrosine in Cardiac Hypercontractility and Arrhythmia Risk

open access: yesFood Frontiers, EarlyView.
Plasma metabolome‐wide Mendelian randomization analysis established a causal link between tyrosine and arrhythmia. GWAS meta‐analysis identified tyrosine‐associated loci linked to cardiovascular risk factors. Animal studies confirmed that oral tyrosine intake modulates heart rhythm via adrenergic signaling activation.
Zhikang Cao   +7 more
wiley   +1 more source

BP control and left ventricular hypertrophy regression in children with CKD.

open access: yesJournal of the American Society of Nephrology, 2014
J. Kupferman   +6 more
semanticscholar   +1 more source

Exposure–Response Modeling and Simulation to Identify Optimal Mavacamten Posology When Coadministered with CYP3A4 and CYP2C19 Inhibitors in Patients with Obstructive HCM

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Mavacamten, a cardiac myosin inhibitor, is primarily metabolized by the cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4, and coadministration with strong CYP3A4 or CYP2C19 inhibitors was contraindicated in patients with obstructive hypertrophic cardiomyopathy (HCM) in the US Prescribing Information. This study assessed the safety and efficacy
Samira Merali   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy